Shevchenko Galina, Hodson Daniel J
Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
Department of Haematology, University of Cambridge, Cambridge, United Kingdom.
Blood Cancer Discov. 2025 Jul 1;6(4):284-287. doi: 10.1158/2643-3230.BCD-25-0160.
In this issue of Blood Cancer Discovery, Varano and colleagues uncover a substantial fraction of high-grade B-cell lymphoma with MYC and BCL2(-BCL6) translocations (so called "double-hit" lymphomas or high-grade B-cell lymphoma-double-hit-BCL2) that lack detectable expression of the B-cell receptor. MYC translocation in these cells is mediated by RAG enzymes, induced in response to silencing of the B-cell receptor in a precursor cell, a feature that renders them resistant to polatuzumab vedotin. See related article by Varano et al., p. 364.
在本期《血癌发现》中，瓦拉诺及其同事发现了相当一部分伴有MYC和BCL2（-BCL6）易位的高级别B细胞淋巴瘤（即所谓的“双打击”淋巴瘤或高级别B细胞淋巴瘤-双打击-BCL2），这些淋巴瘤缺乏可检测到的B细胞受体表达。这些细胞中的MYC易位由RAG酶介导，在前体细胞中因B细胞受体沉默而被诱导，这一特征使它们对泊洛妥珠单抗维达汀耐药。见瓦拉诺等人的相关文章，第364页。
